BACKGROUND AND AIM OF THE STUDY: Few long-term data are available on the Carpentier-Edwards Standard bioprosthesis in the mitral position. As for other bioprostheses, patient age at the time of implant is the main risk factor for structural deterioration, but no published report has analyzed the life-span of these bioprostheses with respect to this parameter. METHODS: A series of 139 patients who underwent mitral valve replacement with the Carpentier-Edwards Standard bioprosthesis between 1978 and 1987 was reviewed. Mean age at implant was 59.6+/-14.7 years (range: 17-79 years). Follow up was 98.4% complete; total follow up was 1,078.7 patient-years (pt-yr) (mean 8.4+/-4.1 years). Mean follow up in the subgroup of patients alive at the time of the survey was 10.4+/-3.4 years. RESULTS: Structural valve deterioration (SVD) occurred in 30 patients, with mean time to onset of deterioration 9.0+/-2.7 years (median 8.7 years). This time was independent of age at the time of implantation. Analysis by age group (< or =35, 36-50, 51-60, 61-65, 66-70, >70 years) showed deterioration to be more frequent in younger subjects (linear rates 7.9, 6.0, 3.3, 2.4, 0.6 and 0.4% pt-yr, respectively). Over the age of 65 years, the risk of SVD no longer varied with age, and was a rare complication. CONCLUSION: The mean time to onset of SVD was independent of patient age at the time of implant. After 65 years, the risk of SVD was low, without any significant variation. The Carpentier-Edwards Standard bioprosthesis may be used in the mitral position in subjects aged over 65 years, and with a low risk of deterioration.
BACKGROUND AND AIM OF THE STUDY: Few long-term data are available on the Carpentier-Edwards Standard bioprosthesis in the mitral position. As for other bioprostheses, patient age at the time of implant is the main risk factor for structural deterioration, but no published report has analyzed the life-span of these bioprostheses with respect to this parameter. METHODS: A series of 139 patients who underwent mitral valve replacement with the Carpentier-Edwards Standard bioprosthesis between 1978 and 1987 was reviewed. Mean age at implant was 59.6+/-14.7 years (range: 17-79 years). Follow up was 98.4% complete; total follow up was 1,078.7 patient-years (pt-yr) (mean 8.4+/-4.1 years). Mean follow up in the subgroup of patients alive at the time of the survey was 10.4+/-3.4 years. RESULTS:Structural valve deterioration (SVD) occurred in 30 patients, with mean time to onset of deterioration 9.0+/-2.7 years (median 8.7 years). This time was independent of age at the time of implantation. Analysis by age group (< or =35, 36-50, 51-60, 61-65, 66-70, >70 years) showed deterioration to be more frequent in younger subjects (linear rates 7.9, 6.0, 3.3, 2.4, 0.6 and 0.4% pt-yr, respectively). Over the age of 65 years, the risk of SVD no longer varied with age, and was a rare complication. CONCLUSION: The mean time to onset of SVD was independent of patient age at the time of implant. After 65 years, the risk of SVD was low, without any significant variation. The Carpentier-Edwards Standard bioprosthesis may be used in the mitral position in subjects aged over 65 years, and with a low risk of deterioration.
Authors: Isaac Wamala; Axel Unbehaun; Christoph Klein; Marian Kukucka; Dirk Eggert-Doktor; Semih Buz; Julia Stein; Simon Sündermann; Volkmar Falk; Jörg Kempfert Journal: Interact Cardiovasc Thorac Surg Date: 2021-05-10